Moderna's Melanoma Win Supports Scancell's Thesis, Not Its Proof
Moderna and Merck's Phase 3 melanoma success supports the idea of combining cancer vaccines with checkpoint inhibitors. Scancell's off-the-shelf approach remains clinically distinct and still needs randomized Phase 3 validation.
A successful Phase 3 melanoma trial from Moderna and Merck strengthens the scientific case for pairing a cancer vaccine with checkpoint inhibition, but it does not validate Scancell's iSCIB1+ by itself. The two programs use different technologies, treat different disease settings and have very different levels of evidence.
In INTerpath-001, Moderna's personalized mRNA therapy intismeran plus Merck's pembrolizumab reduced the risk of recurrence or death by 42% compared with pembrolizumab alone. At 24 months, recurrence-free survival was 82.2% with the combination and 70.0% with pembrolizumab alone. The randomized study enrolled 1,137 patients whose high-risk melanoma had been completely removed by surgery.
Scancell's iSCIB1+ is an off-the-shelf DNA immunotherapy rather than a vaccine manufactured from each patient's tumor. It is being developed for advanced unresectable melanoma in combination with nivolumab and ipilimumab. Immediate availability could be an operational advantage over personalized manufacturing, but that convenience does not establish equivalent efficacy.
The current Scancell evidence comes from the open-label Phase 2 SCOPE study. Its reported progression-free-survival comparison used 39 patients and a historical control, not a randomized concurrent group. That makes the result useful for designing a larger trial, but unsuitable for a direct efficacy comparison with INTerpath-001.
Scancell says the U.S. Food and Drug Administration cleared its investigational new drug application for a registrational Phase 3 study and granted Fast Track designation. The company also received authorization from the U.K. regulator. Its pipeline page says the global trial was expected to begin in the third quarter of 2026, while mature Phase 2 data are expected in the first quarter of 2027.
The read-through from Moderna and Merck is therefore about mechanism and trial strategy. A large randomized study showed that adding a vaccine can improve outcomes beyond checkpoint therapy alone. It does not answer whether Scancell's shared-antigen DNA design will work in later-stage disease, whether its historical-control advantage will survive randomization, or how safety and manufacturing will compare.
For Scancell investors, the decisive evidence remains enrollment and results from the company's own Phase 3 trial. INTerpath-001 lowers the scientific skepticism around the broader vaccine-plus-checkpoint concept, while leaving Scancell's clinical and financing risks intact.